A detailed history of Aqr Capital Management LLC transactions in Precigen, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 15,893 shares of PGEN stock, worth $11,919. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,893
Previous 50,002 68.22%
Holding current value
$11,919
Previous $79,000 81.01%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.91 - $1.88 $31,039 - $64,124
-34,109 Reduced 68.22%
15,893 $15,000
Q2 2024

Aug 14, 2024

BUY
$1.27 - $1.75 $22,983 - $31,669
18,097 Added 56.72%
50,002 $79,000
Q1 2024

May 15, 2024

BUY
$1.21 - $1.75 $38,605 - $55,833
31,905 New
31,905 $46,000
Q3 2023

Nov 14, 2023

SELL
$1.08 - $1.85 $60,719 - $104,010
-56,222 Reduced 39.36%
86,614 $122,000
Q2 2023

Aug 14, 2023

SELL
$0.96 - $1.4 $204,123 - $297,680
-212,629 Reduced 59.82%
142,836 $164,000
Q1 2023

May 15, 2023

SELL
$0.88 - $2.19 $168,459 - $419,233
-191,431 Reduced 35.0%
355,465 $376,000
Q4 2022

Feb 14, 2023

SELL
$1.27 - $2.26 $92,062 - $163,827
-72,490 Reduced 11.7%
546,896 $831,000
Q3 2022

Nov 14, 2022

BUY
$1.41 - $2.79 $184,124 - $364,332
130,585 Added 26.72%
619,386 $1.31 Million
Q2 2022

Aug 15, 2022

BUY
$1.15 - $2.53 $252,538 - $555,585
219,599 Added 81.57%
488,801 $655,000
Q1 2022

May 16, 2022

BUY
$1.91 - $3.98 $99,373 - $207,071
52,028 Added 23.96%
269,202 $568,000
Q4 2021

Feb 14, 2022

BUY
$3.53 - $5.5 $508,291 - $791,956
143,992 Added 196.76%
217,174 $806,000
Q3 2021

Nov 15, 2021

BUY
$4.99 - $6.55 $109,884 - $144,237
22,021 Added 43.04%
73,182 $365,000
Q2 2021

Aug 16, 2021

SELL
$6.24 - $8.22 $219,729 - $289,450
-35,213 Reduced 40.77%
51,161 $334,000
Q1 2021

May 17, 2021

BUY
$6.74 - $10.95 $582,160 - $945,795
86,374 New
86,374 $595,000

Others Institutions Holding PGEN

About PRECIGEN, INC.


  • Ticker PGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 208,150,000
  • Market Cap $156M
  • Description
  • Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...
More about PGEN
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.